Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Quantinno Capital Management LP

Quantinno Capital Management LP grew its position in Becton, Dickinson and Company (NYSE:BDX) by 35.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,442 shares of the medical instruments supplier’s stock after purchasing an additional 2,752 shares during the period. Quantinno Capital Management LP’s holdings in Becton, Dickinson and Company were worth $2,369,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wesbanco Bank Inc. boosted its position in shares of Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 48 shares during the period. S.A. Mason LLC grew its holdings in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after purchasing an additional 50 shares in the last quarter. Hillsdale Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after purchasing an additional 50 shares in the last quarter. Americana Partners LLC boosted its position in shares of Becton, Dickinson and Company by 3.5% during the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 52 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Piper Sandler lowered Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Raymond James lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Friday, May 2nd. Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Finally, Barclays decreased their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating for the company in a research report on Monday, April 7th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $231.44.

Becton, Dickinson and Company Trading Down 0.2%

NYSE:BDX opened at $176.72 on Wednesday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock’s fifty day moving average price is $201.75 and its two-hundred day moving average price is $220.01. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a market cap of $50.65 billion, a P/E ratio of 29.36, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.17 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.35%. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares of the company’s stock, valued at $964,107.36. This trade represents a 8.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Byrd sold 459 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. This trade represents a 6.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,878 shares of company stock valued at $636,393 over the last ninety days. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.